Cariprazine Publications 2006-2018

Non-clinical

Chemistry
Physico-chemical characterization of a novel group of dopamine D3/D2 receptor ligands, potential atypical antipsychotic agents
Deák K, Takács-Novák K, Kapás M, Vastag M, Tihanyi K, Noszál B

Discovery of cariprazine (RGH-188): A novel antipsychotic acting on dopamine D3/D2 receptors

Neurochemistry
Cariprazine (RGH-188), a dopamine D3 receptor preferring D3/D2 dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile
J Pharmacol Exp Ther 333: 328-340, 2010

Occupancy of dopamine D2 and D3 and serotonin 5-HT1A receptors by the novel antipsychotic drug candidate, cariprazine (RGH-188), in monkey brain measured using positron emission tomography
Psychopharmacology 218: 579-587, 2011

In vitro and in vivo comparison of [3H](+)-PHNO and [3H]-raclopride binding to rat striatum and lobes 9 and 10 of the cerebellum: A method to distinguish dopamine D3 from D2 receptor sites
Kiss B, Horti F, Bobok A
Synapse 65: 467-478, 2011

Synapse 67: 258-264, 2013

Long-Term Effects of Cariprazine Exposure on Dopamine Receptor Subtypes
Choi YK, Adham N, Kiss B, Gyertyán I, Tarazi FI
CNS Spectrums 19: 268-277, 2014

Long-term effects of aripiprazole exposure on monoaminergic and glutamatergic receptor subtypes: comparison with cariprazine
Choi YK, Adham N, Kiss B, Gyertyán I, Tarazi FI
CNS Spectrums, 22: 484-494, 2017

Effects of cariprazine on extracellular levels of glutamate, GABA, dopamine, noradrenaline and serotonin in the medial prefrontal cortex in the rat phencyclidine model of schizophrenia studied by microdialysis and simultaneous recordings of locomotor activity
Kehr J, Yoshitake T, Ichinose F, Yoshitake S, Kiss B, Gyertyán I, Adham N
Pharmacology

**RGH-188, a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents**


*Neurochemistry International* **59**: 925-935, 2011

**Cariprazine, a dopamine D3-receptor-preferin partial agonist, block phenycyclidine-induced impairments of working memory, attention set shifting, and recognition memory in the mouse.**

Zimnisky R, Chang G, Gyertyán I, Kiss B, Adham N, Schmauss C

*Psychopharmacology* **226**: 91-100, 2013

**Cariprazine (RGH-188), a D3-preferring dopamine D3/D2 receptor partial agonist antipsychotic candidate demonstrates anti-abuse potential in rats**

Román V, Gyertyán I, Sághy K, Kiss B, Szombathelyi Z

*Psychopharmacology* **226**: 285-293, 2013

**Attenuation of anhedonia by cariprazine in the chronic mild stress model of depression**

Papp M, Gruca P, Lason-Tyburkiewicz M, Adham N, Kiss B, Gyertyán I

*Behav Pharmacol* **25**: 567-574, 2014

**Cariprazine exerts antimanic properties and interferes with dopamine D2 receptor β-arrestin interactions**

Gao Y, Peterson S, Masri B, Hougland MT, Adham N, Gyertyán I, Kiss B, Caron MG and El-Mallakh RS

*Pharma Res Per* **3**: e00073, 1-10, 2014

**Cariprazine delays ouabain-evoked epileptiform spikes and loss of activity in rat hippocampal slices**

El-Mallakh RS, Payne RS, Schurr A, Gao Y, Lei Z, Kiss B, Gyertyán I, Adham N

*Psychiatry Res* **229**: 370-373, 2015

**Effects of cariprazine, a novel antipsychotic, on cognitive deficit and negative symptoms in a rodent model of schizophrenia symptomatology**

Neill JC, Grayson B, Kiss B, Gyertyán I, Ferguson P, Adham N

*Eur Neuropsychopharmacol* **26**: 3-14, 2016

**The dopamine D3-preferring D2/D3 dopamine receptor partial agonist, cariprazine, reverses behavioral changes in a rat neuro-developmental model for schizophrenia**

Watson DJG, King MV, Gyertyán I, Kiss B, Adham N, Fone KC

*Eur Neuropsychopharmacol* **26**: 208-224, 2016

**Cariprazine exhibits anxiolytic and dopamine D3 receptor-dependent antidepressant effects in the chronic stress model**

Duric V, Banasr M, Franklin T, Lepack A, Adham N, Kiss B, Gyertyán I, Duman RS

*Int J Neuropsychopharmacol* **20**: 788-796, 2017

**The effects of cariprazine and aripiprazole on PCP-induced deficits on attention assessed in the 5-choice serial reaction time task**

Barnes S, Young J, Markou A, Adham N, Gyertyán I, Kiss B

*Psychopharmacology* **235**: 1403-1414, 2018
**Pharmacokinetic**

_Sensitive LC-MS/MS methods for the quantification of RGH-188 and its active metabolites, desmethyl- and didesmethyl-RGH-188 in human plasma and urine_

Pázsztor Mészáros G, Ágai-Csongor É, Kapás M  

**Clinical**

**Schizophrenia**

_An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: A phase II, randomized clinical trial_  
*Schizophr Res* **152**: 450-457, 2014

_Cariprazine in acute exacerbation of schizophrenia: A fixed-dose, phase 3, randomized, double-blind, placebo- and active-controlled trial_  
*J Clin Psychiatry* **76**: e1574-e1582, 2015

_Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: Results from an international, phase III clinical trial_  

_Cariprazine in the treatment of schizophrenia: A proof-of-concept trial_  

_Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial_  
Durgam S, Earley W, Li R, Li D, Lu K, Laszlovszky I, Fleischhacker WW, Nasrallah HA  
*Schizophr Res* **176**: 264-271, 2016

_The effect of cariprazine on hostility associated with schizophrenia_  
Citrome L, Durgam S, Lu K, Ferguson P, Laszlovszky I  

_Cariprazine as monotherapy for the treatment of predominant negative symptoms in patients with schizophrenia: A randomized, double-blind, active-comparator controlled trial_  
*Lancet* **389**: 1103-1113, 2017

_Evaluation of the long-term safety and tolerability of cariprazine in patients with schizophrenia: results from a 1-year open-label study_  
*CNS Spectrums* **23**: 39-50, 2018


**Negative Symptoms of Schizophrenia: Constructs, Burden, and Management**


**Mania**


Earley W, Durgam S, Lu K, Debelle M, Laszlovszky I, Vieta E, Yatham LN

*J Affect Disord* **215**: 205-212, 2017

**The safety and tolerability of cariprazine in patients with bipolar I disorder: A 16-week open-label study**  
*J Affect Disord* **225**: 350-356, 2018

**Clinically relevant response and remission outcomes in cariprazine-treated patients with bipolar I disorder**  
*J Affect Disord* **226**: 239-244, 2018

**Schizophrenia & Mania**

Global improvement with cariprazine in the treatment of bipolar I disorder and schizophrenia: a pooled post hoc analysis  

**Bipolar Depression**

An 8-week randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of cariprazine in patients with bipolar I depression  

**Major Depression add-on**

Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: A randomized, double-blind, placebo-controlled study in adult MDD patients  

Efficacy of adjunctive low-dose cariprazine in major depressive disorder: A randomized, double-blind, placebo-controlled trial  
Fava M, Durgam S, Earley W, Lu K, Hayes R, Laszlovszky I, Németh G  
*Int Clin Psychopharmacol* published online, 2018

Cariprazine augmentation to antidepressant therapy in major depressive disorder: Results of a randomized, double-blind, placebo-controlled trial  
Earley W, Guo H, Németh G, Harsányi J, Thase M  
*Psychopharmacology Bulletin* 2018 (in press)

**Human Pharmacokinetic**

Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [11C]-(+)-PHNO  
*Psychopharmacology* **233**: 3503-3512, 2016

Clinical pharmacology study of cariprazine (MP-214) in patients with schizophrenia (12-week treatment)  
Open access
Health Technology Assessment (HTA)

Quality-adjusted life year difference in patients with predominant negative symptoms of schizophrenia treated with cariprazine and risperidone


General

Cariprazine – a milestone of the Hungarian drug research and unique possibility for the treatment of predominant negative symptoms of patients with schizophrenia.

A new chemical entity, developed by Gedeon Richter Plc. in Hungary received market authorization approval from FDA in schizophrenia and bipolar mania indications (Published in Hungarian with English abstract)

Laszlovszky I, Németh G

Gyógyszerészet 59: 643-646, 2015